Imbruvica Market Overview
Introduction
Imbruvica (ibrutinib) is a targeted cancer therapy developed by Pharmacyclics, an AbbVie company, and Janssen Biotech. It is a first-in-class Bruton's tyrosine kinase (BTK) inhibitor that is primarily used for the treatment of various B-cell malignancies, including chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL), Waldenström's...
Arabic
Français
Español
Português
Deutsch
Türkçe
Dutch
Italiano
Russian
Romaian